131 related articles for article (PubMed ID: 20534308)
1. Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?
Farsetti S; Zanazzi M; Caroti L; Rosso G; Larti A; Marcucci R; Fedi S; Rogolino A; Cellai AP; Abbate R; Bertoni E; Salvadori M
Transplant Proc; 2010 May; 42(4):1381-2. PubMed ID: 20534308
[TBL] [Abstract][Full Text] [Related]
2. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
Gonzalez F; Espinoza M; Herrera P; Rocca X; Reynolds E; Lorca E; Roessler E; Hidalgo J; Espinoza O
Transplant Proc; 2010; 42(1):270-2. PubMed ID: 20172327
[TBL] [Abstract][Full Text] [Related]
3. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
4. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
5. Determinants of fasting total serum homocysteine levels in liver transplant recipients.
Akoglu B; Wondra K; Caspary WF; Faust D
Exp Clin Transplant; 2006 Jun; 4(1):462-6. PubMed ID: 16827644
[TBL] [Abstract][Full Text] [Related]
6. Plasma homocysteine levels in renal transplant patients on tacrolimus therapy.
Akbas SH; Tuncer M; Gurkan A; Yucetin L; Yavuz A; Demirbas A; Ersoy F; Gultekin M; Yakupoglu G; Akaydin M
Transplant Proc; 2004; 36(1):159-60. PubMed ID: 15013332
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
Montagnino G; Sandrini S; Casciani C; Schena FP; Carmellini M; Civati G; Rigotti P; Cossu M; Altieri P; Salvadori M; Federico S; Stefoni S; Cambi V; Albertazzi A; Buoncristiani U; Berloco P; Segoloni G; Boschiero L; Sparacino V; Donati D; Turello E; Dal Canton A; Ponticelli C
Transplant Proc; 2005 Mar; 37(2):788-90. PubMed ID: 15848532
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum homocysteine and other parameters in renal transplant patients.
Nouri-Majalan N; Masoumi R; Nafisi R; Nogh H; Ghafari A; Moghaddasi S
Transplant Proc; 2009 Sep; 41(7):2826-8. PubMed ID: 19765447
[TBL] [Abstract][Full Text] [Related]
9. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
Montagnino G; Sandrini S; Iorio B; Schena FP; Carmellini M; Rigotti P; Cossu M; Altieri P; Salvadori M; Stefoni S; Corbetta G; Ponticelli C
Nephrol Dial Transplant; 2008 Feb; 23(2):707-14. PubMed ID: 17890244
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia in liver transplant recipients: prevalence and multivariate analysis of predisposing factors.
Herrero JI; Quiroga J; Sangro B; Beloqui O; Pardo F; Cienfuegos JA; Prieto J
Liver Transpl; 2000 Sep; 6(5):614-8. PubMed ID: 10980061
[TBL] [Abstract][Full Text] [Related]
12. Increased asymmetric dimethylarginine serum levels are associated with acute rejection in kidney transplant recipients.
Esposito C; Grosjean F; Torreggiani M; Maggi N; Esposito V; Migotto C; Mangione F; Tinelli C; Dal Canton A
Transplant Proc; 2009 Jun; 41(5):1570-3. PubMed ID: 19545681
[TBL] [Abstract][Full Text] [Related]
13. Effect of folate, vitamin B6, and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients.
Biselli PM; Sanches de Alvarenga MP; Abbud-Filho M; Ferreira-Baptista MA; Galbiatti AL; Goto MT; Cardoso MA; Eberlin MN; Haddad R; Goloni-Bertollo EM; Pavarino-Bertelli EC
Transplant Proc; 2007 Dec; 39(10):3163-5. PubMed ID: 18089344
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Levy G; Schmidli H; Punch J; Tuttle-Newhall E; Mayer D; Neuhaus P; Samuel D; Nashan B; Klempnauer J; Langnas A; Calmus Y; Rogiers X; Abecassis M; Freeman R; Sloof M; Roberts J; Fischer L
Liver Transpl; 2006 Nov; 12(11):1640-8. PubMed ID: 16598777
[TBL] [Abstract][Full Text] [Related]
15. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
[TBL] [Abstract][Full Text] [Related]
16. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
17. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.
Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B
Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
